Benitec Q3 net loss $4.4M; 9 subjects enrolled in OPMD study; on track for BB-301 dosing in 2H2023

Benitec Biopharma Inc.

2023-Q3 EPS reported -$0.67 revenue$68,000

Net loss of $4.4M ($0.16/shr) in Q3 2023 vs $3.3M ($0.40/shr) in Q3 2022; cash $6.6M at Mar 31, 2023.
9 subjects enrolled in OPMD Natural History Study in the U.S.; pace supports BB-301 dosing and interim data disclosure in 2H2023.
R&D expenses $3.17M vs $2.17M YoY, driven by GMP manufacturing and Natural History Study; operating loss $4.4M.
Expects FDA IND response for BB-301 in Q2 2023; Canadian site activation pending REB approval.
CEO Jerel Banks to present at OPMD International Conference in Tel Aviv on May 16, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Benitec Biopharma Inc. reported financial results for Third Fiscal Quarter ended March 31, 2023.

Period: Third Fiscal Quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 15, 2023 Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended March 31, 2023.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Benitec Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-144217

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.